• Alparslan Kurtul, Adil Hakan Ocek, Sani Namik Murat, Mikail Yarlioglues, Muhammed Bora Demircelik, Mustafa Duran, Gokhan Ergun, and Serkan Cay.
• Department of Cardiology, Ankara Education and Research Hospital, Ankara, Turkey alpkurtul@yahoo.com.
• Angiology. 2015 Mar 1; 66 (3): 278-85.

AbstractLow serum albumin (SA) levels are associated with increased cardiovascular mortality. We investigated whether baseline SA levels are associated with no-reflow following primary percutaneous coronary intervention (pPCI). A total of 536 patients (aged 60 ± 13 years; 74% men) who underwent pPCI were enrolled. The patients were divided into 2 groups: no-reflow and normal-reflow. No-reflow was defined as thrombolysis in myocardial infarction ≤2 flow. Admission SA levels were significantly lower in the no-reflow group than in the normal-reflow group (3.55 ± 0.44 vs 4.01 ± 0.32 mg/dL, P < .001). Also, high-sensitivity C-reactive protein (hsCRP), creatinine, creatine kinase myocardial band isoenzyme, and troponin T were significantly higher while hemoglobin and left ventricular ejection fraction (LVEF) were significantly lower in the no-reflow group. In multivariate analysis, SA level remained an independent predictor of angiographic no-reflow (odds ratio 0.114, 95% confidence interval 0.032-0.405, P = .001) together with LVEF, hsCRP, and baseline culprit artery patency. Admission SA level was an independent predictor of no-reflow after pPCI. © The Author(s) 2014.

41 keywords...

hide…